Q-omics provides the consensus-scored USP24 profile across patient tissues and cancer cell-line models. USP24 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, USP24 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, USP24 RNA expression shows 20,915 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where USP24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP24 survival associations across molecular data types. USP24 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP24 RNA expression–survival associations across cancer types. High USP24 expression shows unfavorable associations in LIHC, MESO and KIRP, but favorable associations in KIRC, UCS and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for USP24 RNA expression.
This table summarizes USP24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for USP24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP24 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in HNSC, STAD and LIHC. The HNSC box plot shows higher USP24 RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with USP24 in patient tissues and cancer cell lines. In patient samples, USP24 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, USP24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
